Daiichi Sankyo (4568) - DS-8201 Moves to Phase 2 for Gastric Cancer
Last week, Daiichi Sankyo (4568 JP) announced that its highly promising anti-cancer drug, DS-8201, has a second pivotal trial, this time moving to...
319 Views
Industrial Capsule: Pharmaceuticals in Japan
Industry’s growth facilitated by healthcare spending as Japan’s society agesThe revenue of Japanese pharmaceutical producers continued to grow in...
211 Views
Not All Players Are Equal in the Plasma Industry
According to Allied Market Research, the IVIG (intravenous IG) market was valued at US$7.86bn and is expected to reach US$12.36bn by 2022. IVIG is...
421 Views
Global Pharmaceuticals: Valuations, Assets and Leverage Up - Margins Down
We examined ten years of accounting and valuation data for the pharmaceutical companies around the world with sales of US$100m+ and created...
565 Views
Large-Cap Names that Have Gotten a Lot More Volatile Recently....
We screened for large-cap names in Japan that have recently seen a spike in volatility. We calculated Beta over the last 6 months and compared it...
381 Views